G6 Materials launches Breathe+ Pro advanced antimicrobial graphene air filtration system

G6 Materials Corp., a high-tech company with expertise in advanced materials and developing innovative composites for a wide range of industrial uses, today announced the launch and immediate availability of the Breathe+ Pro Advanced Antimicrobial Graphene Air Filtration System. 

Key Highlights, include: 

  • Breathe+ Pro Advanced Antimicrobial Graphene Air Filtration System is now available at breatheplus.tech and on Amazon

  • Our advanced air purification system removes microbes1, dust particles, smog, dander, pollen as well as volatile organic compounds (VOC)2 from the air.

  • Antiviral and antibacterial efficacy verified by independent tests by The Intertek Group.

  • Our patented Graphene Filter removes 99.9% of the pathogenic microorganisms.

  • Optimized for spaces up to 1,500 sq. ft., making it perfect for the home and office.

  • Our patented air filtration technology could tap into an estimated US$25.97 billion market

The Breathe+ Pro Air Purifier utilizes innovative air filters that contain activated carbon with graphene oxide coating (“Graphene Filter”) developed by G6’s research team. This coating is designed to enhance the efficacy of the air filter in capturing bioaerosol particles. As supported by a wealth of scientific knowledge, graphene oxide exhibits profound antibacterial and antiviral properties. Besides the activated carbon with graphene coating, the Breathe+ Pro air purifier also includes a pre-filter, a medical-grade H13 True HEPA filter, as well as an activated carbon filter.

The antiviral and antimicrobial efficacy of the Breathe+ Pro Air Purifier was verified by independent testing conducted by The Intertek Group plc  ("Independent Lab Test”) and previously reported in a G6 news release on September 7, 2021. According to the results of the Independent Lab Test, the Breathe+ Pro Air Purifier equipped with Graphene Filter removed 99.9% of the pathogenic microorganisms (model viruses and bacteria) over the duration of the test.

Breathe+ Pro performs multiple air changes per hour to effectively remove pathogens, dust, and other harmful contaminants. It is optimized for large spaces up to 1,500 sqft., making it an ideal solution for residential and commercial spaces like classrooms, offices, kitchens, basements, warehouses, and large living rooms.

The Breathe+ Pro Advanced Antimicrobial Graphene Air Filtration System is a showcase of the Company’s pending patent (US20210346831A1) technology that has a tremendous opportunity to tap into the market of air filtration systems.  This market is expected to reach an estimated US$25.97 billion by 2030 and is expected to expand at a CAGR of 8.1 percent from 2022 to 2030, as outlined in a recent 'Research and Markets' report. The market is primarily driven by increasing air pollution levels, coupled with the outbreak of the COVID-19 pandemic and the rising awareness pertaining to the benefits of air purifiers.

Dr. Daniel Stolyarov, President & Co-CEO of G6 Materials Corp. commented, “We are thrilled to launch our highly anticipated Breathe+ Pro Advanced Antimicrobial Graphene Air Filtration System and excited about the prospects of commercialising our patented graphene based technology. Today’s launch of Breathe+ marks an important milestone for G6-Materials, as we continue to execute on our mission to deliver a retail consumer product, that is capable of making both our homes and offices a cleaner and safer environment.  Graphene has proven to have extraordinary antiviral and antibacterial properties, making it more efficient in killing germs.

“Perhaps just as important a milestone for G6, our disruptive technology marks a new approach to air filtration that utilizes activated carbon with a coating of graphene oxide that can be easily scaled up for a wide range of industrial applications. We have tackled the complexity of air filtration with a robust evidence-based approach and will work to demonstrating our patented technology within many industrial sectors,” concluded Dr. Stolyarov.